|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01498 PURAPHARM
Nominal 
0.450 0.000 (0.000%) | 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Turnover | 172,295 | -17.017% | 382,090 | 406,859 | 448,069 | 659,592 |
| Cost of Sales | (77,172) | -18.220% | (176,948) | (190,230) | (185,365) | (236,239) |
| Gross Profit | 95,123 | -16.015% | 205,142 | 216,629 | 262,704 | 423,353 |
| 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | (2,423) | (12,804) | (3,022) | -- | |
| Change in FV & Impairment on Others | (744) | -- | 997 | (8,083) | (11,906) | (84,624) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | (312) | (145) | 0 | 0 | |
| Profit / (Loss) before Taxation | (20,486) | 38.747% | (29,144) | (102,312) | (119,182) | (117,192) | |
| Taxation | (1,320) | -66.335% | (6,295) | (3,769) | (1,032) | (4,685) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (21,806) | 16.697% | (35,439) | (106,081) | (120,214) | (121,877) | |
| 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Net Finance Costs / (Income) | 9,148 | -29.315% | 23,365 | 27,114 | 23,708 | 26,667 |
| Depreciation & Amortisation | 20,251 | -6.660% | 54,586 | 48,591 | 48,661 | 50,139 |
| Directors' Emoluments | -- | -- | 7,759 | 11,677 | 7,354 | 12,470 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified (Modified Report) | Unqualified (Modified Report) | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -5.520 | 16.702% | -8.970 | -26.850 | -30.470 | -30.950 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.263 | 0.202 | 0.224 | (0.037) |
| NBV per share ($) | 0.257 | -- | 0.281 | 0.387 | 0.652 | 1.017 |
| Remarks: | Real time quote last updated: 11/09/2025 14:58 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD -21,806 |
| %Change | 16.697% |
| EPS / (LPS) | HKD -0.055 |
| NBV Per Share ($) | HKD 0.257 |